Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Washington University School of Medicine Genentech |
---|---|
Information provided by: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00133107 |
This study is to determine whether efalizumab 1.0mg/kg given by subcutaneous injection for 12 weeks is effective in treating oral lichen planus.
This is a 20 week, single center, open-label pilot study to enroll 5 subjects.
Condition | Intervention |
---|---|
Lichen Planus, Oral |
Drug: efalizumab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Single Center, Open-Label, Pilot Study Evaluating the Safety and Effectiveness of Subcutaneous Efalizumab in the Treatment of Oral Lichen Planus |
Estimated Enrollment: | 5 |
Study Start Date: | January 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | Michael P. Heffernan, MD | Washington University School of Medicine |
Study ID Numbers: | LP-efalizumab |
Study First Received: | August 19, 2005 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00133107 |
Health Authority: | United States: Food and Drug Administration |
Mouth Diseases Lichen Planus Exanthema Skin Diseases |
Oral lichen planus Stomatognathic Diseases Skin Diseases, Papulosquamous Lichen Planus, Oral |
Lichenoid Eruptions |